Compare DexCom, Inc. (DXCM) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Teradyne, Inc. — how do they compare? DexCom, Inc. trades at $77.67 (market cap $28.06B), while Teradyne, Inc. trades at $323.42 (market cap $53.56B). The key difference: Teradyne, Inc. is the larger of the two by market cap, and Teradyne, Inc. pays a 0.15% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TER | |
|---|---|---|
Market Cap | $28.06B | $53.56B |
Sector | Health | Technology |
52-Week High | $89.53 | $483.84 |
52-Week Low | $54.84 | $90.15 |
Enterprise Value | $27.03B | $53.39B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Teradyne (TER) trades at $353.23, up 3.55% today, with a bearish technical signal but strong fundamental performance. Recent earnings beats and a 64.52% analyst buy rating support optimism, though high valuation ratios like a P/E of 63.47 and negative net cash flow trends pose concerns. The stock is positioned near its pivot point of $354, with support at $347 and resistance at $360.
Outlook: Growth driven by AI and semiconductor testing demand offers upside to the $453.60 consensus target, but elevated valuations and cash flow challenges present risks. Investors should weigh robust profitability against potential volatility from market sentiment and execution hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
